Latest News and Press Releases

Novo Nordisk has filed a lawsuit against telehealth firm Hims & Hers for patent infringement and putting patients’ lives at stake with knockoff drugs.

Bagsværd, Denmark, 5 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...

The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safet

Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the US Securities and Exchange Commission

Bagsværd, Denmark, 4 February 2026 –The execution of Novo Nordisk A/S’ overall share repurchase programme for 2026 of up to DKK 15 billion will be initiated on 4 February 2026. As part of this, Novo...

Today Novo Nordisk A/S has issued its 2025 annual report. The report is available here: https://www.novonordisk.com/investors/annual-report.html

We are very encouraged by the promising early uptake from the US launch of Wegovy® pill, and we remain confident in our ability to drive volume growth

In 2025, Novo Nordisk’s sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and...

CagriSema demonstrated both superior HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in the trial.

Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S.